ReviewInternational journal of nanomedicine2026
Targeting the Epithelial Alarmin Axis with Biomedical Nanoparticles: A New Frontier in Allergic Asthma Therapy.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic asthma is a chronic inflammatory airway disease driven by type 2 immune responses, whose pathogenesis correlates with the release of epithelial alarm proteins-thymic stromal lymphopoietin (TSLP), interleukin-25 (IL-25), and interleukin-33 (IL-33)-by airway epithelial cells following barrier injury. This paper systematically reviews the cutting-edge applications of nanoparticles (NPs) in targeting the epithelial alarmin signaling axis and its downstream immune cells, including dendritic cells, macrophages, Th2 cells, and regulatory T cells. By systematically reviewing research progress on nanoparticles in allergic asthma treatment, this review provides crucial theoretical support and technical frameworks for developing precise, efficient, and less-side-effect asthma therapies. It offers forward-looking guidance for advancing asthma treatment from laboratory to clinical translation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.